Spain and Italy are shifting the use of the Oxford / Astrageneca vaccine to shifts for people over the age of 60, which will complicate countries’ efforts to expand their vaccination programs.
The decision by Madrid and Rome on Wednesday night, before the start of the European Medicines Agency, said there was a link between a very rare blood clot in the brain and AstraZeneca Jab.
The EMA, the EU’s regulator of pharmaceuticals, has not changed its direction on who will receive the vaccine, but noted that “so far most cases have been reported. [of blood clots] It occurs in women under the age of 60 within two weeks of vaccination.
France and Germany have previously restricted the use of jab for more than 55 and 60s, respectively – other vaccines such as Bioentech / Pfizer and a new one. One shot inoculation Johnson and Johnson will suffice to lag behind the EU’s vaccination program.
The UK, which is well ahead of the EU in the vaccine rollout, suddenly Change its guidelines Through the AstraZeneca vaccine on Wednesday, people aged 18-29 are being offered alternative jobs. Sweden and Finland only allowed its use for more than 65 years, while Denmark and Norway suspended its use until at least the following week.
Spain’s decision to use the AstraZeneca vaccine only for people over the age of 60 only reversed the country’s policy a few weeks ago – until last month it banned the use of jabs by people over the age of 55.
Prime Minister Pedro Sanchez announced on Tuesday that the new position, which supports most parts of the country, could make it more difficult to achieve his goal – the prime minister announced on Tuesday that he would vaccinate 33 million people at the end of August. .
Currently, the 6.4-meter Spaniards have received at least one dose of the Covid-19 vaccine. Of these, more than 2 million got little AstraZeneca jobs, the use of which has accelerated in recent weeks.
Health Minister Carolina Darius says people under the age of 0 have already received their first shots of garbage. The country has not yet decided whether to give AstraZeneca or any other vaccine.
Italy’s health ministry also issued new guidelines overnight stating that the AstraZeneca vaccine should be given “preferred use” in people aged 60 and over. The guideline identified the risk of clots and acknowledged that it was low, and the risk of severe covid-1 of increases with age.
Italian officials told a news conference Wednesday night that the risk-benefit ratio was still significant enough for the vaccine to be given. Italy more initially limited the use of this vaccine to younger patients and removed the age limit as more data became available.
Rome’s new guidelines make it clear that those who have already received a dose of AstraZeneca shots will have to finish their vaccination with the same job regardless of age.
On Wednesday, AstraZeneca acknowledged the findings from the EMA and the UK’s Medicines and Health Care Product Regulatory Agency, noting that more than 200 meters of shots were administered worldwide with a relatively low number of side effects.
The Anglo-Swedish drugmaker said it was working with world authorities to better understand the mechanism of action of side effects. The EMA has ordered further studies on the subject, to be conducted at the University of Utrecht in Rotterdam and the University of Erasmus.
The World Health Organization also said on Wednesday that the link was commendable but could not be confirmed and that the benefits of the vaccine outweighed its risks.